01 Vaccination Coverage for Std The number of government initiatives is increasing to contain the STD epidemic in various regions. These initiatives include regular screening guidelines and vaccination coverage for hepatitis A, hepatitis B, human papillomavirus, and herpes zoster virus, among others. The vaccination coverage for adults and adolescents helps reduce the overall disease burden in the region, which may adversely affect market growth. According to the CDC, the HPV vaccine could aid in the prevention of 32,100 cases of cancer every year. In the U.S., herpes zoster vaccination coverage among adults aged 50 and above and adults aged 60 and above was 24.1% and 34.5%, respectively, in 2018, similar to 2017 estimates.Overall, herpes zoster vaccination coverage among adults increased from 14.4% to 34.5% between 2010 and 2018, indicating an increase in coverage. Similarly, the vaccination coverage of HBV was found to be around 67% in 2018, which is below the Healthy People 2020 target of 90% but still acts as a restraining factor for market growth. HPV vaccination increased from 2.1% in 2011 to 26.3% in 2018 among men and 20.7% in 2010 to 52.8% in 2018 among women aged 19–26.
01 Government Initiatives Encouraging Early Diagnosis and Treatment The governments of developed economies are undertaking initiatives to promote the early diagnosis of STDs. The Sexually Transmitted Infections National Strategic Plan is a ground-breaking, first-of-its-kind five-year plan aimed at reversing the United States' recent fast increase in STIs. The STI Plan offers a vision for dealing with the STI issue and objectives, goals, and techniques. Indicators with measurable targets are also included to track progress. According to national statistics from the United States, the STI Plan focuses on gonorrhea, chlamydia, syphilis, and HPV, which have the highest morbidity rates, the most persistent and widespread STI disparities, and the greatest impact on people's health.This national strategy focuses on raising awareness about STIs and providing access to high-quality, low-cost STI screening, diagnosis, and treatment. Another major STI HIV is the subject of a separate HIV National Strategic Plan. The HIV National Strategic Plan is a blueprint for ending the U.S. HIV epidemic by 2030. Similarly, the Viral Hepatitis National Strategic Plan is focused on hepatitis B and C, which can be transmitted sexually, and many more. Therefore, based on nationwide statistics, the plan identifies populations with the disease burden of viral hepatitis to enable federal agencies and other stakeholders to target their resources to achieve the largest impact.
May 2026 Roche expanded its molecular diagnostics portfolio with advanced sexually transmitted infection (STI) testing solutions featuring multiplex PCR capabilities for faster and more accurate pathogen detection.
March 2026 Abbott introduced enhanced molecular diagnostic platforms supporting rapid detection of multiple sexually transmitted infections, improving accessibility and efficiency in clinical testing workflows.
October 2025 Hologic expanded its Aptima® STI testing portfolio with upgraded molecular diagnostic solutions designed to improve screening accuracy for infections including chlamydia and gonorrhea.
June 2025 BD (Becton, Dickinson and Company) strengthened its diagnostic testing portfolio by expanding molecular platforms for infectious disease detection, including sexually transmitted infections.